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Inbred mice have been an extremely successful tool for basic immunology, but much less so as models of
disease. Thus, to maximize the use of immunologic approaches to improve human health, we need more
strategically directed efforts in human immunology. This would also open up new opportunities for basic
research.Immunology as a branch of the biological
sciences has advanced tremendously
over the last 50 or so years. In this time,
clonal selection has advanced from the-
ory to established fact and the basic
structures of antibodies and T cell recep-
tors have been determined, together with
their remarkable (and thus far, unique)
mechanisms of diversification. A whole
system of innate immune receptors and
responses has been discovered and
elucidated very rapidly, and lymphocytes
and other hematopoetic cells can now
be subdivided into at least 15 different
distinct types. Dozens of cytokines and
chemokines have been identified as me-
diators of cellular communication and
we are the proud possessors of 350 CD
antigens. A field that was once known
chiefly for its impenetrable jargon, the
byzantine complexity of its experiments,
acrimonious disputes, and excessive the-
orizing is now the very model of a modern,
superbly integrated, and rich biological
field, one of the most successful in biol-
ogy (we still have the impenetrable jargon,
but, oh well). We can even claim to have
saved the most lives through vaccines (al-
beit indirectly, as most were formulated
before immunology could offer much
help) and helped bring about a whole
new type of pharmacology in the form of
specific antibodies as drugs, not to men-
tion the promise of direct immunomodula-
tion made possible by knowledge of spe-
cific pathways.
And yet, amid this euphoria, there is
a serious problem, which is that virtually
none of the advances in basic immunol-
ogy cited above have been incorporated
into standard medical practice; special-
ized clinics, yes, to an extent, but
you can go to the most prestigious medi-
cal center in the world and ask ‘‘How ismy immune system?’’ and, after a short
period of eye rolling and looks of amused
incomprehension, you might (if they
don’t just throw you out) be offered
awhite blood cell count (which you should
probably decline). Ask about blood
lipids, though, and you’ll be greeted with
warm smiles, minor bloodletting, and
morality tales about ‘‘good’’ and ‘‘bad’’
cholesterol.
So what’s the story here? Is this be-
cause the immune system is not impor-
tant for health? No, at least since AIDS
and bubble boys, everyone and their
grandmother knows that the immune sys-
tem is central to health and that a particu-
lar deficiency or misregulation can have
severe consequences. Which is also not
news to the millions of people suffering
from the almost ninety different types of
autoimmunity or more than 100 inherited
immune deficiencies or increased sus-
ceptibility to infectious diseases or cancer
because of drug treatments or aging.
It is also becoming clear that many dis-
eases that were not previously thought of
as immunological, such as atherosclero-
sis or Alzheimer’s disease, have a basis
in immunological mechanisms. The list
of these will only grow as more research
is done. In fact, people are so aware of
(and worried) about their immune system
that there is a booming business in prod-
ucts labeled ‘‘immune boosters’’ available
at pharmacies and health food stores near
you. And yet there can be no basis for
such a claim unless there are ‘‘metrics’’
of immune function that can show such
a boost. A central thesis of this essay
will be that immunologists should estab-
lish metrics of immunological health in
humans (and mice too, for that matter) in
order to both better understand the dis-
eases that we study and to make whatImmunity 29,we know more accessible to the public
and the general medical community.
Overreliance on the Mouse Model
Howdidwe arrive at this state of affairs? A
good case can be made that the mouse
has been so successful at uncovering
basic immunologic mechanisms that now
many immunologists rely on it to answer
every question. Where it was once com-
mon to use a variety of species, there is
now such an abundance of reagents
available in mouse immunology that one
has to have an overpowering reason to
work in any other species, including
humans. It also has raised the bar of
evidence required for journals and grant
reviews, as pointed out by Steinman and
Mellman (2004) and by Hayday and Peak-
man (2008). This has skewed the field so
much that most clinically trained immu-
nologists keep at least a few (and usually
a lot more) mice in the ‘‘back room’’ so
that they can have a steady flow of pa-
pers, grant funding, etc., and some have
abandoned human work entirely as
a lost cause. But this is just the price of
progress, no? Well, except that mice
are lousy models for clinical studies.
This is readily apparent in autoimmunity
(von Herrath and Nepom, 2005) and in
cancer immunotherapy (Ostrand-Rosen-
berg, 2004), where of dozens (if not hun-
dreds) of protocols that work well in
mice, very fewhavebeensuccessful in hu-
mans. Similarly, in neurological diseases,
the mouse models have also been disap-
pointing (Schnabel, 2008).
Why has the mouse been so unsuc-
cessful as a clinical model? A number of
possibilities have been put forward. One
is that the use of inbred strains creates
a wealth of homozygous recessive de-
fects that skew the regulation of theDecember 19, 2008 ª2008 Elsevier Inc. 835
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pom, 2005). Another potential culprit is
the artificiality of many disease-inducing
protocols (Quintana-Murci et al., 2007),
and third is the sheer evolutionary dis-
tance (65 million years) between mice
and humans and the likelihood that the
immune system of a short-lived, ground-
dwelling mammal that can replicate
quickly may be substantially different
than that of a long-lived, somewhat higher
off-the-ground mammal that replicates
very slowly (and thus has more of an evo-
lutionary investment in individual survival).
In this regard, Mestas and Hughes (2004)
have carefully delineated the many differ-
ences between mice and humans with re-
spect to various immunemarkers, as have
recent reports contrasting human versus
mouse phenotypes (von Bernuth et al.,
2008; Cohen et al., 2006) in specific
gene deficiencies.
Although it is not clear which of these
possible explanations is most important,
it seems that mouse-human differences
are not even being studied systematically.
We seem to be in a state of denial where
there is so much invested in the mouse
model that it seems almost unthinkable
to look elsewhere, and yet, if we had
objective criteria for particular human
responses, we might be able to use
mice or other animal models more appro-
priately. One possible answer could lie
in the renewed interest in ‘‘humanized’’
mice, which in most cases means
immune-deficient mice into which are in-
troduced either human hematopoetic
stem cells or white blood cells. Although
promising, it should not be assumed that
such mice are equivalent to a human im-
mune system in any respect unless it is
demonstrated to be so by a variety of
objective measures. Many of these can
come only from developing metrics of
human immune function. Thus one very
important reason to develop such metrics
is that they would allow us to use any
particular animal model with much more
confidence.
The Human ‘‘Model’’
This argument leads inevitably to the con-
clusion that if we are to make more rapid
progress in clinically useful immunology
and metrics for immunological health,
we need to encourage more efforts in hu-
man immunology and somehow compen-
sate for all the disadvantages that have836 Immunity 29, December 19, 2008 ª2008discouraged so many people in our field.
Here, a good illustration of what can hap-
pen is the field of human genetics. Long
ago, in the 1970s, human genetics was
one of the least ‘‘happening’’ fields
around. There was really not much you
could do in most cases besides describ-
ing a mutation and constructing a family
tree. Among geneticists, human genetics
was considered a backwater compared
to what could be done in bugs, flies, and
worms. Then, gene cloning came along
and especially the Human Genome Pro-
ject (I’m compressing things a bit here)
and suddenly, genes could be identified
andmechanistic work could be done, and
so forth. This has transformed the field
and hardly a day goes by now without
some new discovery in human genetics.
This is largely because the Genome Pro-
ject put in place a massive chunk of in-
frastructure that made looking for genes
and polymorphisms almost trivial. And
so, people could focus on more interest-
ing things. The other useful lesson of the
Genome Project is that it showed that
the typical academic lab is not the be-
all, end-all of how science should be
done, but that more industrial models
can, in some cases, be more appropriate.
It is worth remembering that this was
a pretty hot debate at the time, as many
thought that the ‘‘big science’’ model
being proposed for the Genome Project,
with its emphasis on economies of scale,
would fatally pollute biological science as
we knew it then. Luckily, the ‘‘big science’’
proponents won that argument (Collins
et al., 2003; with significant help from
Craig Venter and Celera), or we would still
be working toward finishing the human
genome today. The point is that although
the relatively small academic labs as we
know and love them are great for innova-
tion and out-of-the-box thinking, some
problems in biology (and other sciences
for that matter), particularly those that in-
volve a great deal of repetitive assays
and data collection, are much better
suited to a larger-scale organization and
execution. The data are both more uni-
form and considerably cheaper.
What to Do?
Hopefully, the preceding discussion has
convinced the reader that mouse models
are not the answer to everything in immu-
nology and that we need to make greater
efforts in human immunology if we are toElsevier Inc.realize the potential health benefits. But
how to do this is an important question.
Naturally, one could just increase funding
for what’s being done now and that would
certainly help, but I could argue that like
the recent history of human genetics, we
could be much bolder. In addition, even
with massive new funding, it’s pretty clear
that human immunology will never ‘‘catch
up’’ to mouse immunology if they pursue
parallel paths, with each lab doing ‘‘its
own thing’’ largely independent of every-
one else. This is because there are just
too many reagents and tools available to
mouse immunology and nowhere near
the restrictions and limitations that are
involved in human work.
Instead, I think a good case can be
made for taking some very different
approaches in human immunology that
take advantage of its strengths and work
around its weaknesses. So, what are the
strengths? These are, simply, that (1) bil-
lions of people screen themselves for ill-
nesses every day and that those who are
most ill visit doctors and hospitals and
while there contribute millions of blood
specimens. (2) Many thousands of healthy
volunteers can be recruited for studies of
‘‘normal’’ people that can be assayed in
parallel. (3) Hundreds of millions of people
are vaccinated every year and this repre-
sents a valuable resource for the study
of normal immune systems ‘‘perturbed’’
in a safe way. (4) Specific immunological
illnesses have been studied intensively—
almost 90 different autoimmune syn-
dromes have been described as well as
more than 120 inherited immune defi-
ciencies. Thousands of infectious dis-
eases affect humans pathologically, with
new variants or whole new organisms
arising regularly. We also harbor thou-
sands of commensal bacteria in our bod-
ies and at least some of these influence
immunological functions for good or ill.
Lastly, as more and more diseases are
found to have an immunological compo-
nent, it is even more imperative that the
workings of the human immune system
(or its failings) be more fully understood
and incorporated into basic medical
practice.
This leads to an argument for a broad-
scale ‘‘systems’’ approach to immunology
in humans that can use high-throughput
immune-monitoring assays to perform
uniform analyses across many different
clinical samples (blood usually), and those
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the basic parameters of immunological
health. These will benefit from the many
assays that we have available that can
assess dozens of soluble cytokines, dis-
tinguish between 350 cell-surface pro-
teins (CD antigens), separate the 15+ dis-
tinct types of whole blood cells, isolate
many signaling pathways, and survey the
expression of all 25,000+ genes and regu-
latory RNAs. Comparing gene expression
patterns in normal individuals versus pa-
tients with autoimmune disorders has al-
ready proved fruitful in identifying aberrant
cytokine patterns linked to these diseases
and suggests therapeutic options (Allan-
taz et al., 2007). Further genetic analysis
with single-nucleotide polymorphisms
(SNPs) will also be valuable, at least in
the long term, although it should be noted
that patient care is a ‘‘real time’’ activity
and that the subtleties of multigenic dis-
orders may be too problematic to be of
muchuse in theclinic. Specifically, studies
of susceptibility loci other than HLA in
human autoimmunity have shown very
modest risk factors, rendering this kind
of information not immediately useful
clinically, although it certainly can point
to commonalities and drug-treatment
strategies eventually.
Why focus on defining immunological
health versus mechanisms of disease?
Because I think that’s ‘‘what’s missing
from this picture’’ in all this, and given
the variations in immune parameters in
people, we need to get a grip on this
before we can properly understand the
perturbations of many diseases. Although
some of this is ‘‘built into’’ all analyses as
the control population, it hasn’t really
been tackled as an end in itself. And yet,
it has to be defined if we are ever to give
physicians the ‘‘metrics’’ needed to an-
swer the question posed at the beginning
of this essay.
So, how can we define immunological
health? First by searching through all the
biomarkers mentioned and finding ones
that delineate healthy individuals from
those with any of the various diseases
mentioned (much as has been started al-
ready via gene expression data [Allantaz
et al., 2007]). Or more simply, health is
the absence of disease and the more dis-
ease phenotypes that can be integrated
into the same data set, the more you
should be able to identify the warning
signs of a system that is malfunctioning.
A well-known example of this is the loss
of CD4+ T cells in advanced HIV infec-
tion-AIDS, which leaves the victim open
to all kinds of opportunistic infections.
This example also illustrates a likely tru-
ism here, which is that the immune system
is made up of many interacting cell types
and the failure of any one of these is likely
to have deleterious consequences for the
health of that individual. This suggests
that we will need to develop a battery of
functional tests for each cell type or at
least enumerate them by flow cytometry.
A functional assay is ideal because you
not only count the cells of that type but
you test them for a particular attribute or
attributes that essentially integrate over
many potential defects, inherited or ac-
quired. Ultimately, these cellular assays
may be replaced by a simple biomarker
(a particular cytokine or gene, etc.) or
just the number of cells of a particular
phenotype; but perhaps not. So this
would seem to be a useful adjunct to the
other data sets. Thus, at the end of this,
one could imagine a normal range of func-
tional activity, together with correlative
biomarkers that define the useful range
of a given cell type, on either side of which
are examples of where the cell doesn’t
work as well, as illustrated by one or
more disease states. This could be re-
duced to a ‘‘score’’ for each cell type
that could then turn into a useful series
of clinical tests, as shown in Figure 1.
But many scientific benefits could come
from such data as well, such as how the
system as a whole (or parts of it) responds
to the many possible perturbations. This
would tell us about how the different com-
ponents interact with each other. This
may or may not reproduce what we have
deduced about cellular interactions from
mouse studies, but also would have the
ability to reveal interactions that are en-
tirely novel. It would be particularly inter-
esting to monitor how the various new
immune modulatory drugs change an in-
dividual’s overall system and could also
show why some people respond to a par-
ticular drug but others do not. Here, the
diversity of human genetics and immune
responses could provide a rich source of
new insights into how the immune system
functions in the face of constant chal-
lenges from the environment.
Another important component of this is
to develop the informatics infrastructure
that is able to handle this amount of infor-
mation and perhaps most critically
integrate the different types of data in
the search for markers and patterns of
markers that correlate with particular
disease states. This points to another
benefit, which is to find commonalities
between different diseases that depend
on similar mechanisms; this may not cor-
relate with a particular type of disease as
they are categorized now (largely by in-
spection), but may get to a deeper under-
standing of the underlying causes and
lead to potential drug treatments more
rapidly (Chaussabel et al., 2008; Tenen-
baum et al., 2008).
Another promising area of informatics is
that of ‘‘text mining,’’ where various data
can be culled from the literature to create
a kind of general ‘‘meta-analysis’’ of the
literature (Muller et al., 2004).
Specifics
How to implement this approach? Obvi-
ously, more NIH funding would be needed
and there are already some very forward-
looking efforts to encourage human im-
munology ongoing at NIH, particularly
the Cooperative Centers for Translational
Research and Biodefense created 6 years
ago (disclaimer: the author receives fund-
ing from this program). But one basic step
Figure 1. Representative Assay for a Particular White Blood Cell
Here a given white blood cell is assayed for either a function or an array of biomarkers in both normal and
diseased/aged individuals such that a range from overactive to underactive properties is registered. For
the major cell types, it is likely that a deficiency in any one of them will disable the entire system in
some way.Immunity 29, December 19, 2008 ª2008 Elsevier Inc. 837
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ing facilities at all major research medical
schools because that’s where the blood
samples are being taken and there can
be more direct links with the research
projects at that site. Although there are
a number of such facilities, there is not
yet enough of a national or international
program to link them together and to stan-
dardize (and validate) assays, although
a very good beginning has been made
by the Cancer ImmunotherapyMonitoring
Program (http://www.c-imt.org/content/
view/20/26/). Bioinformatics standards
are also needed as well as the deposition
of relevant data after a reasonable ‘‘black-
out’’ period and/or publication. At Stan-
ford University, we have set upwhat could
be a prototype facility with these features
(the Human Immune Monitoring Core),
but the need for a broad and uniform
approach is ever more apparent if we
are to realize all the benefits of this ap-
proach quickly. This type of coordination
and standardization is also important
with respect to clinical trials, and here
the Immune Tolerance Network (http://
www.immunetolerance.org/) has done
this very well. It also would be useful to
have a website dedicated to reports of
human-mouse differences or similarities
in immune function. With a national or
international effort, we could, at much
less cost than the Human Genome
Project, provide something like the rich-
ness of that data infrastructure to create
a great and continuing resource for hu-
man immunology. Efforts along these
lines could easily fit into the concept of
‘‘personalized medicine’’ together with
the analysis of signaling pathways, solu-
ble biomarkers, and genetics (Hood
et al., 2004).838 Immunity 29, December 19, 2008 ª2008Concluding Remarks
Immunologists have long emphasized the
potential benefits for human health of
basic research in our field. Although the
mousemodel hasbeen spectacularly suc-
cessful in advancing our understanding of
basic immunological mechanisms, its re-
cord in formulating clinically useful proto-
cols is much less impressive. Thus, to fully
realize the potential benefits of immunol-
ogy for human health, we need to place
more emphasis on human studies and
make greater efforts to allow it to flourish.
This could also create a rich resource for
future studies of new immunological prin-
ciples, especially as humans live ‘‘in na-
tura’’ (Quintana-Murci et al., 2007) more
or less, outbred and exposed to many
more diseases than laboratory mice.
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